Cost-Utility of Doxorubicin and Cyclophosphamide versus Gemcitabine and Paclitaxel for Treatment of Patients with Breast Cancer in Iran

Hatam, Nahid; Askarian, Mehrdad; Javan-Noghabi, Javad; Ahmadloo, Niloofar; Mohammadianpanah, Mohammad

추천

검색

자료유형: 학술저널

저자정보: Hatam, Nahid (Department of Health Administration, School of Management and Information Sciences, Shiraz University of Medical Sciences) Askarian, Mehrdad (Department of Community Medicine, Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences) Javan-Noghabi, Javad (Department of Health Economics, School of Management and Information Sciences, Shiraz University of Medical Sciences) Ahmadloo, Niloofar (Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences) Mohammadianpanah, Mohammad (Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz University of Medical Sciences)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제18호

발행연도: 2015.1

수록면: 8,265 - 8,270 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: A cost-utility analysis was performed to assess the cost-utility of neoadjuvant chemotherapy regimens containing doxorubicin and cyclophosphamide (AC) versus paclitaxel and gemcitabine (PG) for locally advanced breast cancer patients in Iran. Materials and Methods: This cross-sectional study in Namazi hospital in Shiraz, in the south of Iran covered 64 breast cancer patients. According to the random numbers, the patients were divided into two groups, 32 receiving AC and 32 PG. Costs were identified and measured from a community perspective. These items included medical and non-medical direct and indirect costs. In this study, a data collection form was used. To assess the utility of the two regimens, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (EORTC QLQ-C30) was applied. Using a decision tree, we calculated the expected costs and quality adjusted life years (QALYs) for both methods; also, the incremental cost-effectiveness ratio was assessed. Results: The results of the decision tree showed that in the AC arm, the expected cost was 39,170 US$ and the expected QALY was 3.39 and in the PG arm, the expected cost was 43,336 dollars and the expected QALY was 2.64. Sensitivity analysis showed the cost effectiveness of the AC and ICER=-5535 US$. Conclusions: Overall, the results showed that AC to be superior to PG in treatment of patients with breast cancer, being less costly and more effective.

#Breast cancer #cost-utility #neoadjuvant therapy #doxorubicin #cyclophosphamide #gemcitabine #paclitaxel

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Hatam, Nahid

소속기관 Department of Health Administration, School of Management and Information Sciences, Shiraz Universit